

Yifang Hu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1532994/publications.pdf>

Version: 2024-02-01

12
papers

26,287
citations

1039406

9
h-index

1199166

12
g-index

12
all docs

12
docs citations

12
times ranked

52459
citing authors

#	ARTICLE	IF	CITATIONS
1	Methylation Pattern Mediated by m6A Regulator and Tumor Microenvironment Invasion in Lung Adenocarcinoma. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-15.	1.9	25
2	Declined expressions of vast mitochondria-related genes represented by CYCS and transcription factor ESRRA in skeletal muscle aging. <i>Bioengineered</i> , 2021, 12, 3485-3502.	1.4	9
3	Effect of selenium on thyroid autoimmunity and regulatory T cells in patients with Hashimoto's thyroiditis: A prospective randomized-controlled trial. <i>Clinical and Translational Science</i> , 2021, 14, 1390-1402.	1.5	34
4	A Novel S100 Family-Based Signature Associated with Prognosis and Immune Microenvironment in Glioma. <i>Journal of Oncology</i> , 2021, 2021, 1-18.	0.6	8
5	Methylation and Expression of the Exercise-Related TLR1 Gene Is Associated With Low Grade Glioma Prognosis and Outcome. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 747933.	1.6	15
6	Risk Factors for the Relapse of Graves' Disease Treated With Antithyroid Drugs: A Systematic Review and Meta-analysis. <i>Clinical Therapeutics</i> , 2020, 42, 662-675.e4.	1.1	19
7	Analysis of Regulatory T Cell Subsets and Their Expression of Helios and PD-1 in Patients with Hashimoto Thyroiditis. <i>International Journal of Endocrinology</i> , 2019, 2019, 1-11.	0.6	18
8	Associations Between Three CTLA-4 Polymorphisms and Hashimoto's Thyroiditis Risk: An Updated Meta-Analysis with Trial Sequential Analysis. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 224-236.	0.3	13
9	The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2018, 275, 2127-2134.	0.8	14
10	Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome. <i>Journal of Experimental Medicine</i> , 2017, 214, 773-791.	4.2	27
11	limma powers differential expression analyses for RNA-sequencing and microarray studies. <i>Nucleic Acids Research</i> , 2015, 43, e47-e47.	6.5	26,032
12	Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. <i>Genes and Development</i> , 2014, 28, 1337-1350.	2.7	73